<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05034029</url>
  </required_header>
  <id_info>
    <org_study_id>K-2021-001-02</org_study_id>
    <nct_id>NCT05034029</nct_id>
  </id_info>
  <brief_title>Effect of Metformin on Patients With Osteoarthritis</brief_title>
  <official_title>Effect of Metformin on Tibiofemoral Cartilage Volume and Knee Symptoms Among Overweighted Knee Osteoarthritis patients-a Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guangzhou First People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guangzhou First People's Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized controlled trial aims to investigate if metformin has osteoarthritis&#xD;
      protective effects among overweighted knee osteoarthritis patients. The co-primary outcomes&#xD;
      are changes in tibiofemoral cartilage volume and Western Ontario and McMaster Universities&#xD;
      Arthritis Index (WOMAC) from baseline to month 24. The secondary outcomes are changes in&#xD;
      visual analog scale (VAS)-assessed knee pain, tibiofemoral cartilage defect,&#xD;
      effusion-synovitis volume, and tibiofemoral bone marrow lesion from baseline to month 24.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of tibiofemoral cartilage volume from baseline to 24 months follow up</measure>
    <time_frame>Baseline and 24 months follow up</time_frame>
    <description>Tibiofemoral cartilage volume will be assessed on MRI by drawing disarticulation contours around the cartilage boundaries on a section by section basis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of Western Ontario and McMaster Universities Osteoarthritis Index from baseline to 24 months follow up</measure>
    <time_frame>Baseline and 3, 6, 12, 24 months follow up</time_frame>
    <description>The score of Western Ontario and McMaster Universities Osteoarthritis Index is from 0 to 2400, with higher scores mean a worse knee osteoarthritis symptom.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of knee pain visual analog scale from baseline to 24 months follow up</measure>
    <time_frame>Baseline and 3, 6, 12, 24 months follow up</time_frame>
    <description>The score of knee pain visual analog scale is from 0 to 100, with higher scores mean a more severe knee pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of tibiofemoral cartilage defect from baseline to 24 months follow up</measure>
    <time_frame>Baseline and 24 months follow up</time_frame>
    <description>Tibiofemoral cartilage defects will be graded on MRI images using a modified Outerbridge classification.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of effusion-synovitis volume from baseline to 24 months follow up</measure>
    <time_frame>Baseline and 24 months follow up</time_frame>
    <description>Effusion-synovitis volume will be measured on MRI images in the four regions (suprapatellar pouch, central portion, posterior femoral recess, subpopliteal recess) according to the anatomy of the knee joint synovial cavity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of tibiofemoral bone marrow lesion from baseline to 24 months follow up</measure>
    <time_frame>Baseline and 24 months follow up</time_frame>
    <description>Tibiofemoral bone marrow lesion is defined as discrete area of increased signal adjacent to subcortical bone at the tibia and femur on MRI using a semiquantitative (0-3) scoring system.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">262</enrollment>
  <condition>Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Metformin hydrochloride sustained release tablet will administer orally in escalating doses to reduce side-effects and maintain masking: 0.5 g/dag for the first two weeks, 1 g/dag for the next 2 weeks, and then 2 g/dag until the end of the study if tolerated. If the subject cannot tolerate the maximum dose (2 g/day), take their maximum tolerable dose. In case of adverse reaction, the researcher can judge whether the subject needs to reduce or stop the drug according to the specific situation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo will administer the same as the experimental drug.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin hydrochloride sustained release tablets</intervention_name>
    <description>Oral</description>
    <arm_group_label>Metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Meet the American College of Rheumatology (ACR) criteria for symptomatic knee&#xD;
             osteoarthritis assessed by a rheumatologist;&#xD;
&#xD;
          2. Age 50 to 75 years;&#xD;
&#xD;
          3. Body mass index ≥ 24 kg/m2;&#xD;
&#xD;
          4. Knee pain ≥ 20 on a 100 mm visual analogue scale (VAS);&#xD;
&#xD;
          5. Able to listen, speak, read and understand Chinese; capable of understanding the study&#xD;
             requirements and willing to cooperate with the study instructions; able to provide&#xD;
             written, informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Severe radiographic knee OA as grade 3 joint space narrowing according to the&#xD;
             Osteoarthritis Research Society International (OARSI) atlas;&#xD;
&#xD;
          2. Severe knee pain as knee pain ≥ 80 on a 100 mm VAS;&#xD;
&#xD;
          3. Planned knee or hip surgery (including arthroscopy, joint replacement, and joint open&#xD;
             operation) within 2 years;&#xD;
&#xD;
          4. Severe knee trauma history (including arthroscopy, severe injury of knee ligament or&#xD;
             meniscus);&#xD;
&#xD;
          5. Contraindication to MRI scanning (e.g. implanted pacemaker, artificial metal valve or&#xD;
             cornea, aneurysm clipping surgery, arterial dissection, metal foreign bodies in the&#xD;
             eyeball, claustrophobia);&#xD;
&#xD;
          6. Other forms of inflammatory arthritis (e.g. rheumatoid arthritis, psoriatic&#xD;
             arthritis);&#xD;
&#xD;
          7. Active malignant cancer or other life-threatening diseases;&#xD;
&#xD;
          8. Type 1 or type 2 diabetes mellitus;&#xD;
&#xD;
          9. Clinical manifestation of liver dysfunction or alanine aminotransferase/aspartate&#xD;
             aminotransferase exceeding 2 times the upper limit of normal value;&#xD;
&#xD;
         10. Estimated glomerular filtration rate less than 60 ml/min/1.73 m2;&#xD;
&#xD;
         11. Hypoxic state (e.g. chronic heart insufficiency, acute myocardial infarction, heart&#xD;
             failure, chronic obstructive pulmonary disease, cor pulmonale, peripheral vascular&#xD;
             disease);&#xD;
&#xD;
         12. Alcoholism;&#xD;
&#xD;
         13. Pregnancy or lactation;&#xD;
&#xD;
         14. Allergic to metformin hydrochloride;&#xD;
&#xD;
         15. Conditions affecting the absorption of oral drugs (e.g. postgastrectomy and&#xD;
             malabsorption syndrome);&#xD;
&#xD;
         16. Use of metformin in recent 30 days or plan to use metformin in the next 2 years;&#xD;
&#xD;
         17. Use of investigational drug in recent 30 days.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Guangzhou First People's Hospital</name>
      <address>
        <city>Guangzhou</city>
        <zip>510180</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 25, 2021</study_first_submitted>
  <study_first_submitted_qc>September 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 5, 2021</study_first_posted>
  <last_update_submitted>September 2, 2021</last_update_submitted>
  <last_update_submitted_qc>September 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

